CN114599656A - 咪唑烷酮类化合物及其制备方法与应用 - Google Patents

咪唑烷酮类化合物及其制备方法与应用 Download PDF

Info

Publication number
CN114599656A
CN114599656A CN202080074887.2A CN202080074887A CN114599656A CN 114599656 A CN114599656 A CN 114599656A CN 202080074887 A CN202080074887 A CN 202080074887A CN 114599656 A CN114599656 A CN 114599656A
Authority
CN
China
Prior art keywords
cancer
radical
compound
pi3k
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080074887.2A
Other languages
English (en)
Inventor
祖厚贤
宋西镇
陈凯
刘湘永
陈洁
边雅敬
丁列明
王家炳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betta Pharmaceuticals Co Ltd
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Publication of CN114599656A publication Critical patent/CN114599656A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Abstract

如式(Ⅰ)所示的咪唑烷酮类化合物或其立体异构体、几何异构体或互变异构体，或其药学上可接受的盐，含有所述化合物的药物组合物、合成方法及其应用。

Description

PCT国内申请，说明书已公开。

Claims (35)

  1. PCT国内申请，权利要求书已公开。
CN202080074887.2A 2019-11-04 2020-11-04 咪唑烷酮类化合物及其制备方法与应用 Pending CN114599656A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201911066689 2019-11-04
CN2019110666897 2019-11-04
PCT/CN2020/126372 WO2021088845A1 (zh) 2019-11-04 2020-11-04 咪唑烷酮类化合物及其制备方法与应用

Publications (1)

Publication Number Publication Date
CN114599656A true CN114599656A (zh) 2022-06-07

Family

ID=75848226

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080074887.2A Pending CN114599656A (zh) 2019-11-04 2020-11-04 咪唑烷酮类化合物及其制备方法与应用

Country Status (2)

Country Link
CN (1) CN114599656A (zh)
WO (1) WO2021088845A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116867791A (zh) * 2021-01-29 2023-10-10 南京明德新药研发有限公司 三并环类化合物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102762576A (zh) * 2009-09-28 2012-10-31 霍夫曼-拉罗奇有限公司 苯并氧杂氮杂*pi3k抑制剂化合物和使用方法
CN103562210A (zh) * 2011-03-21 2014-02-05 弗·哈夫曼-拉罗切有限公司 对pI3K 110δ具有选择性的苯并氧氮杂*化合物及使用方法
CN107873032A (zh) * 2015-07-02 2018-04-03 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
CN107995911A (zh) * 2015-07-02 2018-05-04 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
WO2019228341A1 (zh) * 2018-05-30 2019-12-05 江苏豪森药业集团有限公司 含三并环类衍生物抑制剂、其制备方法和应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102762576A (zh) * 2009-09-28 2012-10-31 霍夫曼-拉罗奇有限公司 苯并氧杂氮杂*pi3k抑制剂化合物和使用方法
CN103562210A (zh) * 2011-03-21 2014-02-05 弗·哈夫曼-拉罗切有限公司 对pI3K 110δ具有选择性的苯并氧氮杂*化合物及使用方法
CN107873032A (zh) * 2015-07-02 2018-04-03 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
CN107995911A (zh) * 2015-07-02 2018-05-04 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
WO2019228341A1 (zh) * 2018-05-30 2019-12-05 江苏豪森药业集团有限公司 含三并环类衍生物抑制剂、其制备方法和应用

Also Published As

Publication number Publication date
WO2021088845A1 (zh) 2021-05-14

Similar Documents

Publication Publication Date Title
TW202120488A (zh) 作為shp2抑制劑的化合物及其應用
TW202043212A (zh) Shp2抑制劑及其應用
CN111499634B (zh) 一种喹唑啉化合物及其在医药上的应用
CN108884066B (zh) 作为蛋白激酶抑制剂的2，3，5-取代的噻吩化合物
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
CN111171049B (zh) 酪氨酸激酶抑制剂及其用途
EP3741752A1 (en) Tam family kinase /and csf1r kinase inhibitor and use thereof
US20220064161A1 (en) Pyrrolopyridine derivative and use thereof in prevention and treatment of protein kinase-related disease
US20230066011A1 (en) Pyrrolopyrimidine derivative, and pharmaceutical composition for preventing or treating protein kinase-related disease comprising same as active ingredient
CN113164475A (zh) Dyrk1a的大环抑制剂
EP3617204A1 (en) Indoleamine 2,3-dioxygenase inhibitor and application
CN114430740A (zh) Egfr抑制剂、组合物及其制备方法
CN113302196A (zh) Egfr抑制剂及其组合物和应用
US20210040102A1 (en) Imidazo-fused heterocycles and uses thereof
CN113248497A (zh) 用作fgfr4抑制剂的稠环衍生物
JP2023513333A (ja) キノリニル基ホスフィンオキシド化合物、並びにその組成物及び使用
CN114599656A (zh) 咪唑烷酮类化合物及其制备方法与应用
CN114599655B (zh) 咪唑烷酮类化合物及其制备方法与应用
CA3158731A1 (en) Adenosine receptor antagonist compounds
JP2022538901A (ja) ピラゾロン縮合ピリミジン化合物、その製造方法及び使用
CN111377873B (zh) 氨基嘧啶化合物及其制备方法和用途
CN110283174B (zh) 一类PI3Kδ抑制剂及其用途
AU2021296681A1 (en) Novel compound, and pharmaceutical composition for preventing or treating resistant cancer, comprising same
WO2021073498A1 (zh) Egfr抑制剂、组合物及其制备方法
WO2022237871A1 (zh) 咪唑烷酮类化合物的多晶型物、制备方法及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination